ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients
www.eurekalert.org
A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma (PPGL), two rare and potentially life-threatening neuroendocrine tumors.
This is an automated archive made by the Lemmit Bot.

The original was posted on /r/science by /u/FunnyGamer97 on 2025-10-18 19:48:45+00:00.

Original Title: Results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients | Phase II trial finds Belzutifan significantly shrinks advanced, inoperable pheochromocytoma and paraganglioma tumors and improved related symptoms